A phase I study of Lapatinib (GW572016) and topotecan in patients with solid tumors.

被引：0
|
作者：
Erlichman, C
Adjei, AA
Joy, ME
Rubin, SD
Friedman, RA
Ames, MM
Reid, JM
Molina, JR
机构：
[1] Mayo Clin, Rochester, MN USA
[2] GlaxoSmithKline Oncol, Res Triangle Pk, NC USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8994S / 8994S
页数：1
相关论文
共 50 条
  • [21] Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).
    Midgley, R
    Flaherty, KT
    Haller, DG
    Versola, MJ
    Smith, DA
    Koch, KM
    Pandite, L
    Kerr, DJ
    O'Dwyer, PJ
    Middleton, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 213S - 213S
  • [22] Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and-2 Tyrosine Kinases, in Japanese Patients with Solid Tumors
    Nakagawa, Kazuhiko
    Minami, Hironobu
    Kanezaki, Masayuki
    Mukaiyama, Akihira
    Minamide, Yoshiyuki
    Uejima, Hisao
    Kurata, Takayasu
    Nogami, Toshiji
    Kawada, Kenji
    Mukai, Hirofumi
    Sasaki, Yasutsuna
    Fukuoka, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (02) : 116 - 123
  • [23] A phase 1, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen.
    Storniolo, AM
    Burris, H
    Pegram, M
    Overmoyer, B
    Miller, K
    Jones, S
    Silverman, P
    Paul, E
    Loftiss, J
    Pandite, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 18S - 18S
  • [24] A phase II study of lapatinib (GW572016) in recurrent/metastatic (RIM) squamous cell carcinoma of the head and neck (SCCHN).
    Abidoye, O. O.
    Cohen, E. E.
    Wong, S. J.
    Kozloff, M. F.
    Nattam, S. R.
    Stenson, K. M.
    Blair, E. A.
    Day, S.
    Dancey, J. E.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 297S - 297S
  • [25] A phase I dose escalation study of the dual kinase inhibitor GW572016 in combination with paclitaxel
    Jones, SF
    Burris, HA
    Willcutt, NT
    Dickson, NR
    Raefsky, EL
    Greco, A
    Versola, MJ
    Smith, DA
    Pandite, LN
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S83 - S83
  • [26] Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors.
    Tan, BR
    Read, W
    Bergeron, K
    Fracasso, PM
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [27] A phase I study of lapatinib (LPT) and cetuximab (CTX) in patients with CTX-sensitive solid tumors.
    Deeken, John F.
    Wang, Hongkun
    Hwang, Jimmy J.
    Marshall, John
    Subramaniam, Deepa Suresh
    He, Aiwu Ruth
    Weiner, Louis M.
    Hardesty, Rosemarie A.
    Steadman, Kenneth
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Phase I study of docetaxel and topotecan in patients with solid tumors
    Katherine H. Tkaczuk
    William C. Zamboni
    Nancy S. Tait
    Barry R. Meisenberg
    L. Austin Doyle
    Martin J. Edelman
    Petr F. Hausner
    Merrill J. Egorin
    David A. Van Echo
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 442 - 448
  • [30] Phase I study of docetaxel and topotecan in patients with solid tumors
    Tkaczuk, KH
    Zamboni, WC
    Tait, NS
    Meisenberg, BR
    Doyle, LA
    Edelman, MJ
    Hausner, PF
    Egorin, MJ
    Van Echo, DA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) : 442 - 448
12345